For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
All patients with pediatric kidney tumors that have been treated at the Princess Maxima Center and have given informed consent have been included in the study (54) Data exclusions No data was excluded
Replication
For each of the experiments, we specify in the legends the number of replicates conducted.
Randomization Not relevant as no comparisons were made between different experimental groups.
Blinding
All analyses were performed blinded. For instance, H&E stainings were examined by the pathologist without providing any patient information (e.g. tumor type, stage, etc.).
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Validation
Antibodies were validated for use in these systems by the manufacturers who have provided references on each of their
Human research participants
Policy information about studies involving human research participants
Population characteristics
We collected tumors (and matching healthy kidney) from all pediatric patients (age < 18) with kidney tumors entering the Princess Maxima Center. We included in this study male and female patients with different diagnosis, with primary and/or metastatic tumors, patient that underwent different therapy regimens. All details about patients included in the study are mentioned in Supplementary Table 1 .
Recruitment
All children treated in our institute for a renal tumor and signed informed consent was obtained were included.
Ethics oversight
All experiments with human tissue were approved by the medical ethical committee of the Erasmus Medical Center (Rotterdam, the Netherlands).
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation MRTK and Wilms tumour organoids were dissociated into single-cell suspensions using TrypLE Express (Thermo Fisher) supplemented with Rho-kinase inhibitor Y-27632 (10 μM, Abmole). Single-cell suspensions were stained using mouse Alexa-fluor 488 anti-human CD326 EPCAM clone 9C4(1:20, Biolegend) and CD90-APC clone 5E10 (Biolgend, 328113, 1:50) as described.
Instrument
EPCAM-positive and -negative populations were separated using BD FACSAria -Fusion sorter (BD Biosciences). EPCAM positive and CD90 positive populations were separated using MoFlow Astrios (Beckman Coulter).
Software Kaluza Analysis 2.1
Cell population abundance After sorting, both populations were plated in BME and cultured as described in Methods section.
Gating strategy
In contrast to normal kidney tissue, MRTKs do not show epithelial differentiation. Therefore, we separated MRTK cells from contaminating normal kidney cells based on expression of the epithelial marker EPCAM. As for CD90 and EPCAM gating in Wilms tumor organoids, we used unlabelled cells of interest, single-color controls (UltraComp beads ThermoFisher, or partially killed cells of interest) followed by automatic compensation matrix calculation s(fluorescence-minus-one (FMO) controls for each marker).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
